新型降脂药物bempedoic acid

血脂异常是心血管疾病的一个高危因素,目前临床上仍以药物治疗为主要手段。bempedoic acid是一种人工合成的、以口服为给药途径的二羧酸衍生物,其对肝脏三磷酸腺苷-柠檬酸裂解酶(ACL)和腺苷单磷酸-活化蛋白激酶(AMPK)有双重调节作用,很有潜力成为另一个非他汀类的降脂药。多项临床试验研究表明bempedoic acid具有良好的安全性和有效性。主要从bempedoic acid的药物概况、相关背景、合成路线、作用机制和药理作用、临床研究等方面进行介绍。

A new lipid-lowing drug: bempedoic acid

Dyslipidemia is a high risk factor for cardiovascular disease. Currently, pharmacologic therapy is still the main treatment in clinical. bempedoic acid is an oral synthetic dicarboxylic acid derivative. And it is a dual regulators of ACL and AMPK, and it has the potential to become another non-statins lipid-lowing drug. Many clinical studies show that bempedoic acid has a good safety and effectiveness. The drug situation, background, route of synthesis, mechanism and pharmacological action, and clinical trials researches of bempedoic acid are reviewed in this paper.